{"id":604,"date":"2021-08-16T18:04:51","date_gmt":"2021-08-16T18:04:51","guid":{"rendered":"https:\/\/nuwiq.wpengine.com\/hcp\/?page_id=604"},"modified":"2025-03-06T19:34:19","modified_gmt":"2025-03-06T19:34:19","slug":"nuwiq-safety-in-previously-treated-patients-ptps","status":"publish","type":"page","link":"https:\/\/nuwiqusa.com\/hcp\/clinical-evidence\/nuwiq-safety-in-previously-treated-patients-ptps\/","title":{"rendered":"NUWIQ<sup>&reg;<\/sup> &ndash; Safety in Previously Treated Patients (PTPs)"},"content":{"rendered":"\n<h2>ZERO Inhibitors in Previously Treated Patients (PTPs) upon Switching to NUWIQ<sup>1<\/sup><\/h2>\n<ul>\n<li>NUWIQ was shown to be safe in clinical studies that included 135 previously treated patients (PTPs)\n<ul>\n<li>No patients experienced serious or severe reactions to <a href=\"https:\/\/nuwiqusa.com\/hcp\/about-nuwiq\/what-is-nuwiq\/\">NUWIQ<\/a><\/li>\n<li>No deaths reported<\/li>\n<li><a href=\"https:\/\/nuwiqusa.com\/hcp\/about-nuwiq\/molecular-design-implications\/\">No patients developed inhibitors<\/a><\/li>\n<\/ul>\n<\/li>\n<li>FVIII levels can be safely and accurately measured with both the chromogenic and one-stage assays\n<ul>\n<li>No serious or severe reactions to NUWIQ in clinical studies, and no deaths reported<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n","protected":false},"excerpt":{"rendered":"<p>ZERO Inhibitors in Previously Treated Patients (PTPs) upon Switching to NUWIQ1 NUWIQ was shown to be safe in clinical studies&#8230;<\/p>\n","protected":false},"author":23,"featured_media":0,"parent":423,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-604","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Safety in PTPs - NUWIQ\u00ae\ufe0f Official HCP Website<\/title>\n<meta name=\"description\" content=\"Clinical studies show NUWIQ\u00ae is safe for previously treated patients (PTPs) with hemophilia A, with zero inhibitors and no serious reactions. Learn about safety data.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nuwiqusa.com\/hcp\/clinical-evidence\/nuwiq-safety-in-previously-treated-patients-ptps\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Safety in PTPs - NUWIQ\u00ae\ufe0f Official HCP Website\" \/>\n<meta property=\"og:description\" content=\"Clinical studies show NUWIQ\u00ae is safe for previously treated patients (PTPs) with hemophilia A, with zero inhibitors and no serious reactions. Learn about safety data.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nuwiqusa.com\/hcp\/clinical-evidence\/nuwiq-safety-in-previously-treated-patients-ptps\/\" \/>\n<meta property=\"og:site_name\" content=\"NUWIQ\u00ae Healthcare Professionals\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-06T19:34:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nuwiqusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2022\/05\/SocialShare_1200x630.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/clinical-evidence\\\/nuwiq-safety-in-previously-treated-patients-ptps\\\/\",\"url\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/clinical-evidence\\\/nuwiq-safety-in-previously-treated-patients-ptps\\\/\",\"name\":\"Safety in PTPs - NUWIQ\u00ae\ufe0f Official HCP Website\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/#website\"},\"datePublished\":\"2021-08-16T18:04:51+00:00\",\"dateModified\":\"2025-03-06T19:34:19+00:00\",\"description\":\"Clinical studies show NUWIQ\u00ae is safe for previously treated patients (PTPs) with hemophilia A, with zero inhibitors and no serious reactions. Learn about safety data.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/clinical-evidence\\\/nuwiq-safety-in-previously-treated-patients-ptps\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/clinical-evidence\\\/nuwiq-safety-in-previously-treated-patients-ptps\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/clinical-evidence\\\/nuwiq-safety-in-previously-treated-patients-ptps\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clinical Evidence\",\"item\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/clinical-evidence\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Safety in PTPs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/#website\",\"url\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/\",\"name\":\"NUWIQ\u00ae Healthcare Professionals\",\"description\":\"[Antihemophilic Factor (Recombinant)]\",\"publisher\":{\"@id\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/#organization\",\"name\":\"NUWIQ\u00ae (Antihemophilic Factor [Recombinant])\",\"url\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2022\\\/05\\\/SocialShare_1200x630.jpg\",\"contentUrl\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2022\\\/05\\\/SocialShare_1200x630.jpg\",\"width\":1200,\"height\":630,\"caption\":\"NUWIQ\u00ae (Antihemophilic Factor [Recombinant])\"},\"image\":{\"@id\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Safety in PTPs - NUWIQ\u00ae\ufe0f Official HCP Website","description":"Clinical studies show NUWIQ\u00ae is safe for previously treated patients (PTPs) with hemophilia A, with zero inhibitors and no serious reactions. Learn about safety data.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nuwiqusa.com\/hcp\/clinical-evidence\/nuwiq-safety-in-previously-treated-patients-ptps\/","og_locale":"en_US","og_type":"article","og_title":"Safety in PTPs - NUWIQ\u00ae\ufe0f Official HCP Website","og_description":"Clinical studies show NUWIQ\u00ae is safe for previously treated patients (PTPs) with hemophilia A, with zero inhibitors and no serious reactions. Learn about safety data.","og_url":"https:\/\/nuwiqusa.com\/hcp\/clinical-evidence\/nuwiq-safety-in-previously-treated-patients-ptps\/","og_site_name":"NUWIQ\u00ae Healthcare Professionals","article_modified_time":"2025-03-06T19:34:19+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/nuwiqusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2022\/05\/SocialShare_1200x630.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nuwiqusa.com\/hcp\/clinical-evidence\/nuwiq-safety-in-previously-treated-patients-ptps\/","url":"https:\/\/nuwiqusa.com\/hcp\/clinical-evidence\/nuwiq-safety-in-previously-treated-patients-ptps\/","name":"Safety in PTPs - NUWIQ\u00ae\ufe0f Official HCP Website","isPartOf":{"@id":"https:\/\/nuwiqusa.com\/hcp\/#website"},"datePublished":"2021-08-16T18:04:51+00:00","dateModified":"2025-03-06T19:34:19+00:00","description":"Clinical studies show NUWIQ\u00ae is safe for previously treated patients (PTPs) with hemophilia A, with zero inhibitors and no serious reactions. Learn about safety data.","breadcrumb":{"@id":"https:\/\/nuwiqusa.com\/hcp\/clinical-evidence\/nuwiq-safety-in-previously-treated-patients-ptps\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nuwiqusa.com\/hcp\/clinical-evidence\/nuwiq-safety-in-previously-treated-patients-ptps\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nuwiqusa.com\/hcp\/clinical-evidence\/nuwiq-safety-in-previously-treated-patients-ptps\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nuwiqusa.com\/hcp\/"},{"@type":"ListItem","position":2,"name":"Clinical Evidence","item":"https:\/\/nuwiqusa.com\/hcp\/clinical-evidence\/"},{"@type":"ListItem","position":3,"name":"Safety in PTPs"}]},{"@type":"WebSite","@id":"https:\/\/nuwiqusa.com\/hcp\/#website","url":"https:\/\/nuwiqusa.com\/hcp\/","name":"NUWIQ\u00ae Healthcare Professionals","description":"[Antihemophilic Factor (Recombinant)]","publisher":{"@id":"https:\/\/nuwiqusa.com\/hcp\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nuwiqusa.com\/hcp\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/nuwiqusa.com\/hcp\/#organization","name":"NUWIQ\u00ae (Antihemophilic Factor [Recombinant])","url":"https:\/\/nuwiqusa.com\/hcp\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/nuwiqusa.com\/hcp\/#\/schema\/logo\/image\/","url":"https:\/\/nuwiqusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2022\/05\/SocialShare_1200x630.jpg","contentUrl":"https:\/\/nuwiqusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2022\/05\/SocialShare_1200x630.jpg","width":1200,"height":630,"caption":"NUWIQ\u00ae (Antihemophilic Factor [Recombinant])"},"image":{"@id":"https:\/\/nuwiqusa.com\/hcp\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nuwiqusa.com\/hcp\/wp-json\/wp\/v2\/pages\/604","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nuwiqusa.com\/hcp\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/nuwiqusa.com\/hcp\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/nuwiqusa.com\/hcp\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/nuwiqusa.com\/hcp\/wp-json\/wp\/v2\/comments?post=604"}],"version-history":[{"count":0,"href":"https:\/\/nuwiqusa.com\/hcp\/wp-json\/wp\/v2\/pages\/604\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/nuwiqusa.com\/hcp\/wp-json\/wp\/v2\/pages\/423"}],"wp:attachment":[{"href":"https:\/\/nuwiqusa.com\/hcp\/wp-json\/wp\/v2\/media?parent=604"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}